echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > ASCO's innovative first-line treatment for gastric cancer reduces the risk of death by 40%, Zai Lab owns rights in Greater China

    ASCO's innovative first-line treatment for gastric cancer reduces the risk of death by 40%, Zai Lab owns rights in Greater China

    • Last Update: 2021-06-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    ▎The content team editor of WuXi AppTec today, Amgen announced at the ASCO annual meeting the latest results of its ongoing anti-FGFR2b monoclonal antibody therapy bemarituzumab in a phase 2 clinical trial
    .

    The test results showed that at a median follow-up time of 12.
    5 months, the median overall survival (OS) of patients with FGFR2b positive and HER2-negative gastric cancer or gastroesophageal junction cancer (GEJ) who received bemarituzumab and chemotherapy first-line treatment was 19.
    2 Month, this value in the chemotherapy group was 13.
    5 months (n=155, HR=0.
    6, 95% CI: 0.
    38, 0.
    94)
    .

    Adding bemarituzumab extended the patient's median OS by 5.
    7 months
    .

    Gastric cancer is the fourth leading cause of cancer deaths in the world.
    More than 1 million new gastric cancer patients are diagnosed each year, and its incidence is particularly high in Asia
    .

    About 80-85% of patients with advanced gastric cancer and GEJ cancer are HER2 negative, and about 30% of them overexpress FGFR2b
    .

    Bemarituzumab is a monoclonal antibody against FGFR2b
    .

    It has a dual mechanism of action.
    It can not only block the signal transduction of growth factors mediated by FGFR2b by binding to FGFR2b, but also kill cancer cells through antibody-dependent cell-mediated cytotoxicity (ADCC)
    .

    It received the breakthrough therapy designation granted by the FDA in April this year
    .

    Zai Lab has the development rights of this innovative therapy in Greater China and is responsible for the clinical trials of the drug in Greater China
    .

    ▲The mechanism of action of bemarituzumab (picture source: Five Prime's official website) In this phase 2 clinical trial, the combination therapy of bemarituzumab has a more prominent effect on the subgroup of patients with >10% of tumor cells overexpressing FGFR2b.
    This subgroup of patients The median OS was 25.
    4 months, while the control group value was 11.
    1 months (n=96, HR: 0.
    41; 95% CI: 0.
    23, 0.
    74)
    .

    In terms of safety, the number of adverse events in the bemarituzumab+ chemotherapy group (100%) and the chemotherapy group (98.
    7%) was close
    .

    The incidence of adverse corneal events in the Bemarituzumab+ chemotherapy group (67.
    1%) was higher than that in the chemotherapy group (10.
    4%).
    Dry eye symptoms were the most common corneal adverse events, and most corneal adverse events were reversible
    .

    Dr.
    David M.
    Reese, Executive Vice President of Research and Development of Amgen, said: "These latest results demonstrate the clinical benefits of bemarituzumab+chemotherapy combination for patients.
    We look forward to advancing bemarituzumab to the phase 3 clinical development stage
    .

    "Reference: [1] Phase 2 Fight Trial Continues To Show Improved Overall Survival With Bemarituzumab Plus Chemotherapy In Patients With FGFR2b+ Gastric And Gastroesophageal Cancers.
    Retrieved June 4, 2021, from https:// -releases/2021/06/phase-2-fight-trial-continues-to-show-improved-overall-survival-with-bemarituzumab-plus-chemotherapy-in-patients-with-fgfr2b-gastric-and-gastroesophageal-cancers Note: This article is intended to introduce the progress of medical and health research, not a treatment plan recommendation
    .

    If you need treatment plan guidance, please go to a regular hospital for treatment
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.